1. Introduction {#s1}
===============

Congestive heart failure (CHF) is a clinical syndrome marked by venous congestion and maladaptive neurohormonal activation in the setting of left ventricular dysfunction.[@b1] Recent evidence has shown the occurrence of lipid metabolic derangements in this syndrome.[@b2],[@b3] The relationship between lipids and coronary artery disease, both from pathogenesis to risk determination and from treatment to clinical outcomes, is well established.[@b4] However, this is not the case between lipids and CHF. Hyperlipidemia is associated with a higher risk of development of CHF.[@b5]--[@b7] Ironically, newly emerging evidence from randomized clinical trials has shown that lipid lowering therapy does not reduce mortality in CHF;[@b8]--[@b10] instead, high cholesterol levels are associated with better outcomes in CHF.[@b11]--[@b13] This phenomenon is defined as an epidemiologic paradox, and its underlying mechanisms are not fully understood.[@b3]

Venous congestion, due to volume overload can worsen renal function and impair glomerular filtration in CHF.[@b14],[@b15] Venous congestion in CHF also impairs absorption of water, electrolytes, and glucose. We hypothesized that venous congestion in CHF may lead to low lipid levels in CHF due to reduced lipid absorption. Therefore, we analyzed the relationship between lipid levels and right ventricle end diastolic diameter (RVEDD), which is a good indicator of the chronic volume overload status in CHF.

2. Methods {#s2}
==========

This cross-sectional study was approved by the institutional ethics committee and conducted in adherence with local guidelines for good clinical practice. We reviewed the medical records of 442 patients with CHF who were treated in our heart center between January 2005 and March 2010. The diagnosis of CHF was based on clinical symptoms and a combination of clinical signs and echocardiogram. The exclusion criteria were familial hypercholesterolemia, familial hyper-triglyceridemia, terminal illness, chronic liver disease, cachexia, acute myocarditis, acute coronary syndrome, pregnancy, renal function insufficiency \[serum creatinine (SCr) \< 200 µmol/L\], nursing mothers, and sepsis. Patients were also excluded from the analysis when variables (i.e., lipid profile and echocardiographic data) were not available from the same time point (defined as a maximum interval of 7 days). The detailed clinical characteristics and medications are listed in [Table 1](#jgc-11-03-192-t01){ref-type="table"}.

2.1. Laboratory assays {#s2a}
----------------------

Blood samples for lipid level analysis were taken in the morning, and total cholesterol (TCL), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) levels were directly measured with a UNICEL DxC 800 (Beckman Coulter, USA) automatic analyzer system immediately after blood samples were obtained. For quality control, during operation of the Beckman Coulter AU analyzer, at least two levels of lipid control material were tested (a minimum of once a day).

2.2. Echocardiographic measurements {#s2b}
-----------------------------------

All chamber measurements were performed according to guidelines and recommendations by the European Association of Echocardiography.[@b16] The diameter of left atrium (LA) was measured from M-mode, guided by a parasternal long-axis image at the level of the aortic valve. Left ventricle end diastolic diameter (LVEDD was measured from M-mode, guided by parasternal long-axis image at the level of the tip of the mitral valve. Diameter of right atrium (RA) was measured along the minor-axis that was perpendicular to the long axis of RA and extended from the lateral border of RA to the inter-atrial septum in the apical four-chamber view. Right ventricle end diastolic diameter (RVEDD) was measured along the minor-axis in the apical four-chamber view, at a level which was approximately one-third from the base of the ventricle.

###### Clinical characteristics of patients with congestive heart failure (*n* = 442).

  Variables                            Value
  ------------------------ ------------------------------
  Age, yrs                         61.92 ± 14.78
  Female                            223 (40.33%)
  BMI, kg/m^2^                      25.12 ± 3.74
  MI                                100 (22.6%)
  IDC                                88 (19.9%)
  VHD                                75 (17.0%)
  HTN                                70 (15.8%)
  AF                                136 (30.7%)
  DM                                 85 (19.2%)
  NYHA functional class    
   I                                 40 (9.0%)
   II                                92 (20.8%)
   III                              139 (31.4%)
   IV                               171 (38.7%)
  Echocardiographic data   
   LA, cm                          45.08 ± 10.39
   LA/BSA, cm/m^2^                  23.19 ± 5.76
   RVEDD, cm                        37.76 ± 8.89
   RVEDD/BSA, cm/m^2^               19.47 ± 5.08
   RA, cm                          41.43 ± 11.51
   RA/BSA, cm/m^2^                  21.37 ± 6.47
   LVEDD, cm                       55.62 ± 13.84
   LVEDD/BSA, cm/m^2^               28.51 ± 7.26
   LVEF                           47.33% ± 16.38%
  Laboratory test          
   FG, mmol/L                6.06 ± 2.68 (NR: 3.9--6.1)
   TCL, mmol/L                4.23 ± 1.24 (NR \< 5.17)
   TG, mmol/L               1.37 ± 0.98 (NR: 0.20--1.70)
   LDL-C, mmol/L              2.55 ± 1.04 (NR \< 3.20)
   HDL-C, mmol/L            1.07 ± 0.49 (NR 0.80--1.80)
  Medications              
   Furosemide                       252 (57.0%)
   HCTZ                             231 (52.38%)
   Furosemide and HCTZ              125 (28.3%)
   Spironolactone                   36.9 (83.5%)
   Digitalis                        185 (41.9%)
   ACEI                             265 (60.0%)
   ARB                               64 (14.5%)
   CCB                               76 (17.2%)
   β-blocker                        339 (61.30%)
   Warfarin                          89 (20.1%)
   Statin                           158 (35.7%)

Data are expressed as mean ± SD or *n* (%). ACEI: angiotensin-converting enzyme inhibitors; AF: atrial fibrillation/flutter; ARB: angiotensin II receptor blockers; BMI: body mass index; BSA: body surface area; CCB: calcium channel blocker; DM: diabetes mellitus; FG: fasting glucose; HCTZ: hydrochlorothiazide; HDL-C: high-density lipoprotein cholesterol; HTN: hypertension; IDC: idiopathic dilated cardiomyopathy; LA: left atrium; LDL-C: low-density lipoprotein cholesterol; LVEDD: left ventricle end diastolic diameter; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NR: normal range; NYHA: New York Heart Association; RA: right atrium; RVEDD: right ventricle end diastolic diameter; TCL: total cholesterol; TG: triglyceride; VHD: valvular heart disease.

2.3. Statistical analysis {#s2c}
-------------------------

Statistical analysis were carried out using SPSS 16.0 statistical package. The Pearson correlation coefficients were derived. Variables, such as LA, LVEDD, RA, RVEDD, and left ventricular ejection fraction (LVEF) were indexed to the body surface area (BSA). Correlation coefficients were also calculated in subgroups stratified by LVEF (i.e., patient with preserved LVEF and patients with systolic heart failure) and statin treatment (i.e., patients on statin treatment and those not on statin treatment). We also conducted partial correlation using the following as co-variables to rule out any potential bias: age, gender, smoking status, physical activity levels, comorbidities (myocardial infarction, atrial fibrillation/flutter, diabetes mellitus, idiopathic dilated cardiomyopathy, valvular heart disease, and hypertension), and medication use. A multiple linear regression was used to model the dependence of lipid levels on age, gender, statin therapy, and echocardiographic parameters. Standardized coefficients were calculated to reflect the relationship between lipid levels and echocardiographic parameters.

3. Results {#s3}
==========

3.1. Relationship between lipid profile and echocardiographic data in patients with CHF {#s3a}
---------------------------------------------------------------------------------------

The univariate correlation coefficients between variables of patients with CHF are shown in [Figure 1](#jgc-11-03-192-g001){ref-type="fig"}. The analysis using Pearson\'s correlation coefficient indicated that there was a statistically significant linear inverse relationship between concentrations of TCL and RVEDD (*r* = −0.34, *P* \< 0.0001, [Figure 1](#jgc-11-03-192-g001){ref-type="fig"}). The strongest correlation was observed between concentrations of TCL with RVEDD and RA (*r* = −0.36, *P* \< 0.0001, [Figure 1](#jgc-11-03-192-g001){ref-type="fig"}). There was a similar but weaker correlation of concentrations of LDL-C, LDL-C, and TG with RVEDD and RA ([Table 2](#jgc-11-03-192-t02){ref-type="table"}).

![Correlations between total cholesterol and heart chamber size.\
TCL: total cholesterol; RA: right atrium; BSA: body surface area; RVEDD: right ventricle end diastolic diameter; LA: left atrium; LVEDD: left ventricle end diastolic diameter; LVEF: left ventricular ejection fraction.](jgc-11-03-192-g001){#jgc-11-03-192-g001}

###### Correlation between heart chambers and lipid profile in patients with CHF.

                  TG         LDL-C       HDL-C       RA/BSA     RVEDD/BSA      LA/BSA     LVEDD/BSA       LVEF
  ----------- ----------- ----------- ----------- ------------ ------------ ------------ ------------ ------------
  TCL          0.351^\#^   0.896^\#^   0.305^\#^   −0.361^\#^   −0.342^\#^   −0.253^\#^   −0.128^\#^     0.092
  TG                       0.126^\#^    −0.021     −0.329^\#^   −0.341^\#^   −0.233^\#^   −0.129^\#^     0.020
  LDL-C                                  0.057     −0.247^\#^   −0.211^\#^   −0.155^\#^     −0.090       0.053
  HDL-C                                            −0.135^\#^   −0.148^\#^     −0.092       −0.057      0.102\*
  RA/BSA                                                        0.804^\#^    0.592^\#^     0.102\*       −0.079
  RVEDD/BSA                                                                  0.546^\#^    0.178^\#^    −0.124^\#^
  LA/BSA                                                                                  0.246^\#^    −0.167^\#^
  LVEDD/BSA                                                                                            −0.644^\#^

\**P* \< 0.05; ^\#^*P*\<0.01, *n* = 442. BSA: body surface area; HDL-C: high-density lipoprotein cholesterol; LA: left atrium; LDL-C: low-density lipoprotein cholesterol; LVEDD: left ventricle end diastolic diameter; LVEF: left ventricular ejection fraction; RA: right atrium; RVEDD: right ventricle end diastolic diameter; TCL: total cholesterol; TG: triglyceride.

###### Correlations between heart chamber size and lipid profile in CHF patients with preserved LVEF.

                  TG         LDL-C       HDL-C       RA/BSA     RVEDD/BSA      LA/BSA     LVEDD/BSA
  ----------- ----------- ----------- ----------- ------------ ------------ ------------ ------------
  TCL          0.305^\#^   0.893^\#^   0.363^\#^   −0.332^\#^   −0.287^\#^   −0.283^\#^     −0.084
  TG                         0.090      −0.089     −0.311^\#^   −0.316^\#^   −0.186^\#^   −0.185^\#^
  LDL-C                                  0.099     −0.203^\#^    −0.141\*    −0.214^\#^     −0.027
  HDL-C                                             −0.164\*    −0.187^\#^     −0.083       −0.053
  RA/BSA                                                        0.847^\#^    0.569^\#^     0.177\*
  RVEDD/BSA                                                                  0.517^\#^    0.222^\#^
  LA/BSA                                                                                  0.255^\#^

\**P* \< 0.05; ^\#^*P* \< 0.01; *n* = 245. BSA: body surface area; CHF: congestive heart failure; HDL-C: high-density lipoprotein cholesterol; LA: left atrium; LDL-C: low-density lipoprotein cholesterol; LVEDD: left ventricle end diastolic diameter; LVEF: left ventricular ejection fraction; RA: right atrium; RVEDD: right ventricle end diastolic diameter; TCL: total cholesterol; TG: triglyceride.

###### Correlations between heart chamber size and lipid profile in CHF patients with systolic dysfunction.

                  TG         LDL-C       HDL-C       RA/BSA     RVEDD/BSA      LA/BSA     LVEDD/BSA
  ----------- ----------- ----------- ----------- ------------ ------------ ------------ -----------
  TCL          0.418^\#^   0.899^\#^   0.272^\#^   −0.382^\#^   −0.379^\#^   −0.227^\#^   −0.147\*
  TG                       0.172^\#^     0.035     −0.371^\#^   −0.388^\#^   −0.303^\#^    −0.094
  LDL-C                                  0.029     −0.276^\#^   −0.259^\#^     −0.112     −0.142\*
  HDL-C                                              −0.118       −0.121       −0.086      −0.016
  RA/BSA                                                        0.779^\#^    0.606^\#^      0.023
  RVEDD/BSA                                                                  0.558^\#^      0.094
  LA/BSA                                                                                   0.159\*

\**P* \< 0.05; ^\#^*P* \< 0.01; *n* = 197. BSA: body surface area; CHF: congestive heart failure; HDL-C: high-density lipoprotein cholesterol; LA: left atrium; LDL-C: low-density lipoprotein cholesterol; LVEDD: left ventricle end diastolic diameter; LVEF: left ventricular ejection fraction; RA: right atrium; RVEDD: right ventricle end diastolic diameter; TCL: total cholesterol; TG: triglyceride.

3.2. Patients with preserved systolic function versus patients with systolic dysfunction {#s3b}
----------------------------------------------------------------------------------------

In the subgroup analysis, the results were consistent with the previous findings that the strongest correlation for lipid levels was with RVEDD and RA, irrespective of the left ventricle systemic function ([Tables 3](#jgc-11-03-192-t03){ref-type="table"} & [4](#jgc-11-03-192-t04){ref-type="table"}).

However, the correlation between lipid levels and LA were weaker in both subgroups. In patients with preserved LVEF as well as those with LV systolic dysfunction, there was no correlation between LVEDD and lipid levels such as TCL, LDL-C, and HDL-C.

3.3. Patients receiving statin therapy *vs.* patients not receiving statin therapy {#s3c}
----------------------------------------------------------------------------------

The correlation between lipid profile and RVEDD and size of RA were similar in patients with CHF with or without statin treatment ([Tables 5](#jgc-11-03-192-t05){ref-type="table"} & [6](#jgc-11-03-192-t06){ref-type="table"}). However, the correlation between lipid levels and size of LA was weaker in both subgroups. In addition, there was no correlation between LVEDD and lipid levels such as TCL, LDL-C, and HDL-C in patients with CHF irrespective of whether or not they were receiving statin therapy.

3.4. Partial correlation and linear regression between lipid profile and echocardiographic parameters {#s3d}
-----------------------------------------------------------------------------------------------------

The correlation between lipid profile and size of the right heart remained unchanged in partial correlation in which age, gender, smoking status, New York Heart Association (NYHA) functional class, comorbidities and medication use were taken as co-variables ([Table 7](#jgc-11-03-192-t07){ref-type="table"}). In multiple linear regression models, standardized coefficients were calculated. Finally, the relationship between lipid levels and echocardiographic parameters was established, which was consistent with unadjusted results ([Table 8](#jgc-11-03-192-t08){ref-type="table"}).

###### Correlations between heart chamber size and lipid profile in CHF patients not receiving statin therapy.

                  TG         LDL-C       HDL-C       RA/BSA     RVEDD/BSA      LA/BSA     LVEDD/BSA
  ----------- ----------- ----------- ----------- ------------ ------------ ------------ -----------
  TCL          0.339^\#^   0.886^\#^   0.278^\#^   −0.330^\#^   −0.283^\#^   −0.255^\#^    −0.108
  TG                         0.067      −0.026     −0.340^\#^   −0.351^\#^   −0.308^\#^   −0.136\*
  LDL-C                                  0.029     −0.204^\#^    −0.145\*     −0.135\*     −0.069
  HDL-C                                             −0.119\*     −0.118\*      −0.086      −0.052
  RA/BSA                                                        0.774^\#^    0.608^\#^     0.152\*
  RVEDD/BSA                                                                  0.545^\#^    0.177^\#^
  LA/BSA                                                                                  0.226^\#^

\**P* \< 0.05; ^\#^*P* \< 0.01; *n* = 284. BSA: body surface area; CHF: congestive heart failure; HDL-C: high-density lipoprotein cholesterol; LA: left atrium; LDL-C: low-density lipoprotein cholesterol; LVEDD: left ventricle end diastolic diameter; LVEF: left ventricular ejection fraction; RA: right atrium; RVEDD: right ventricle end diastolic diameter; TCL: total cholesterol; TG: triglyceride.

###### Correlations between heart chamber size and lipid profile in patients receiving statin therapy.

                  TG         LDL-C       HDL-C       RA/BSA     RVEDD/BSA      LA/BSA     LVEDD/BSA
  ----------- ----------- ----------- ----------- ------------ ------------ ------------ -----------
  TCL          0.370^\#^   0.922^\#^   0.387^\#^   −0.403^\#^   −0.456^\#^   −0.233^\#^   −0.178\*
  TG                       0.222^\#^    −0.020     −0.310^\#^   −0.330^\#^     −0.121      −0.126
  LDL-C                                  0.137     −0.321^\#^   −0.356^\#^    −0.187\*     −0.143
  HDL-C                                             −0.178\*    −0.237^\#^     −0.099      −0.082
  RA/BSA                                                        0.867^\#^    0.560^\#^      0.030
  RVEDD/BSA                                                                  0.545^\#^     0.184\*
  LA/BSA                                                                                  0.295^\#^

\**P* \< 0.05; ^\#^*P* \< 0.01; *n* = 158. BSA: body surface area; HDL-C: high-density lipoprotein cholesterol; LA: left atrium; LDL-C: low-density lipoprotein cholesterol; LVEDD: left ventricle end diastolic diameter; LVEF: left ventricular ejection fraction; RA: right atrium; RVEDD: right ventricle end diastolic diameter; TCL: total cholesterol; TG: triglyceride.

###### Partial correlations between heart chamber size and lipid profile in patients with CHF.

                  TG         LDL-C        HDL-C       RA/BSA      RVEDD/BSA     LA/BSA     LVEDD/BSA
  ----------- ----------- ------------ ----------- ------------- ------------ ----------- -----------
  TCL          0.350^\#^   0.871 ^\#^   0.356^\#^   −0.283^\#^    −0.379^\#^    −0.082      −0.045
  TG                         0.109       −0.117     −0.2880^\#^   −0.276^\#^    −0.078      −0.065
  LDL-C                                   0.006      −0.237\*     −0.301^\#^    −0.087      −0.131
  HDL-C                                                0.033        0.033        0.051      −0.105
  RA/BSA                                                          0.806^\#^     0.021\*     −0.056
  RVEDD/BSA                                                                    0.267^\#^     0.034
  LA/BSA                                                                                   0.346^\#^

\**P* \< 0.05; ^\#^*P* \< 0.01; *n =* 442. BSA: body surface area; HDL-C: high-density lipoprotein cholesterol; LA: left atrium; LDL-C: low-density lipoprotein cholesterol; LVEDD: left ventricle end diastolic diameter; LVEF: left ventricular ejection fraction; RA: right atrium; RVEDD: right ventricle end diastolic diameter; TCL: total cholesterol; TG: triglyceride.

###### Linear regression of lipid profile and echocardiographic parameters.

  Dependent variables    Predictor   Standardized coefficient   *P* value
  --------------------- ----------- -------------------------- -----------
  TCL                     RA/BSA              -0.361            \< 0.001
  TG                      RV/BSA              -0.357            \< 0.001
  HDL-C                   RV/BSA              -0.145            \< 0.001
  LDL-C                   RA/BSA              -0.247            \< 0.001

TCL: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.

4. Discussion {#s4}
=============

Our study showed that there was an inverse relationship between lipid levels and RA or RVEDD, which was independent of LVEF and heart failure type. This relationship did not exist in patients with coronary heart disease without CHF or with neither CAD nor CHF (unpublished data). This relationship suggested that volume overload might play an important role in lipid metabolism in CHF. To the best of our knowledge, this is the first study providing these results or similar data under a similar setting. We used the following Medical Subject Heading (MeSH) terms: cholesterol, or (cholesterol, LDL), or (cholesterol, HDL), or triglycerides with heart failure to perform a literature search. The search was limited to human studies and clinical trials. Findings similar to this study were not found.

Elevated serum cholesterol levels were shown to be a risk factor for the development of CHF in the Framingham study.[@b5] However, subsequent clinical observational studies suggest that low lipid levels are associated with worse clinical outcomes in CHF, and the inverse relationship between lipid levels and adverse clinical outcomes has been consistently documented in clinical studies.[@b11]--[@b13],[@b17] Three major randomized trials, COntrolled ROsuvastatin multi-NAtional trial in heart failure (CORONA), Gruppo Italiano per lo Studio della Sopravvivenza nell\'Insufficienza Cardiaca (GISSI-HF) and the pitavastatin heart failure study (PEARL study) have directly addressed the issue about lipid lowering therapy in patients with CHF, and failed to show any beneficial clinical effect on mortality in such patients.[@b8]--[@b10] Despite the neutral effect on all-cause or cardiovascular mortality, the efficacy and safety of statin therapy in patients with CHF is still a matter of debate.[@b18],[@b19] Evidence has shown that statin therapy significantly decreases the rate of hospitalization for worsening CHF and increases LVEF compared with placebo.[@b8],[@b19] Our understanding of lipid metabolism in heart failure is certainly incomplete. Several possible mechanisms have been proposed.

Decreased calorie intake and food absorption might be possible reasons for low lipid levels in CHF. In addition, CHF is a metabolically demanding condition. The resting metabolic rate accounts for up to 70% of daily energy expenditure in CHF.[@b20] Increased cardiac and breathing work in chronic heart failure leads to a greater resting metabolic rate and the presence of a catabolic state. In addition, there are several reasons for a worsened nutrition status in patients with CHF.[@b21] First, salt restrictions may result in loss of appetite as food loses its appeal and taste, and fluid restrictions may cause an increase in thirst. Second, patients with CHF also have symptoms that can affect their food intake, for example gastrointestinal symptoms like nausea, loss of appetite, or an early feeling of satisfaction. Third, drugs such as digoxin usually affect food intake and minor degrees of digitalis intoxication can cause anorexia, nausea, and diarrhea.

In addition to the above factors causing malnutrition, venous congestion in the stomach and intestines may play a role in lipid metabolism. It not only leads to hypomotility in the gastrointestinal tract, but also reduces nutrition and bile acid absorption. In order to balance the loss of bile acids, cholesterol is converted by the liver into bile acids, further lowering the level of cholesterol in the body.[@b3] The right ventricular (RV) is highly sensitive to the volume status, thus, it is a good indicator for chronic volume load status.[@b22]

The RV is a thin-walled structure. Unlike left ventricular (LV), RV is able to accommodate varying degree of preload (volume load) without affecting its cardiac output because RV can distend its free wall without evoking the Frank-Starling mechanism to augment cardiac output.[@b23] The RV only relies on the Frank-Starling mechanism to augment cardiac output when a large increase in volume occurs, therefore, RV dilation is more sensitive to volume overload. The RA, being a thin-walled chamber, is also very sensitive to chronic volume overload. In addition, tricuspid regurgitation (TR) also contributes to venous congestion in heart failure. Our finding that CHF patients with severe TR had much lower lipid level than those patients without TR (unpublished data) supports the above notion. The obvious inverse relationship between lipid levels and size of RA, or RV presented in the study, indicates the importance of volume overload, i.e., venous congestion, in lipid metabolism in CHF. However, the relationship between right chamber diameters and volume status merits further investigation.

Low lipid levels and the larger size of RA and RV in heart failure, however, may simply reflect a greater disease severity. Thus, low lipid levels may just reflect nutritional status that also has a prognostic impact.[@b24] As for the right heart, investigations have consistently shown a strong correlation between RV function and mortality in CHF,[@b25]--[@b28] in both ischemic and non-ischemic cardiomyopathy.[@b26],[@b29] Therefore, either low lipid levels or a larger size of RA or RV may be just markers of disease severity and their relationship may not be causal. Another highly plausible explanation is that patients with low lipid levels may have received more aggressive lipid-lowering treatments in order to achieve overall benefits on cardiac function. However, in the subgroup analysis that included CHF patients either receiving statin therapy or not receiving statin therapy, the observed associations remained unchanged in both the CHF groups. The partial correlation analysis also showed the observed associations remain almost the same when statin therapy was used as the co-variable (unpublished data).

These findings suggest that right heart dysfunction or overload may contribute to the impairment of lipid metabolism. More aggressive therapy aiming at relieving right heart dysfunction or overload may be required for patients with lower lipid profiles. However, the hypothesis warrants further investigation.

There are several limitations to the study. First, this is a cross-sectional study, and our results were generated from a hypothesis that offered potential explanations that lipid-lowering therapy failed to show benefit in patients with CHF. Second, a diminished calorie intake might be another reason for low lipid levels in CHF, but we did not record the weight change or calorie intake. Therefore, our study cannot establish the notion that volume overload is the cause of low cholesterol levels in CHF. More data on venous congestion should have been collected, e.g., diameter of hepatic veins and clinical signs of right heart failure. Third, according to heart failure guidelines, there appears to be an under-treatment with beta-blockers and a frequent treatment with digitalis, which may not reflect the clinical practice in the real world. In the future, it may be possible to analyze the interplay between changes in lipid levels, underlying treatment, and changes in volume status in larger cohorts of patients with standardized follow-up.

Our findings suggest an inverse relationship between lipid levels and RVEDD in CHF; however, because this was an observational study, further investigation is needed to verify our results as well as identify a causal relationship, if any.
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